Srinivas Rao - 14 Mar 2023 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
Co-Founder and Chief Scientific Officer
Signature
/s/ Ryan Barrett, Attorney-in-fact
Issuer symbol
ATAI
Transactions as of
14 Mar 2023
Net transactions value
$0
Form type
4
Filing time
16 Mar 2023, 20:27:07 UTC
Previous filing
04 Mar 2022
Next filing
15 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATAI Stock Option Award $0 +600,000 $0.000000 600,000 14 Mar 2023 Common Shares 600,000 $1.18 Direct F1
transaction ATAI Restricted Stock Unit Award $0 +350,000 $0.000000 350,000 14 Mar 2023 Common Shares 350,000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option shall vest as to 25% of the underlying shares on March 14, 2024, and in 36 substantially equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.

Remarks:

Co-Founder and Chief Scientific Officer